Jun. 1 at 4:55 PM
$INAB – The clinical data out of #ASCO2026 is a massive validator: 13-month mPFS in newly diagnosed GBM vs 6.6 months SOC. Science aside, look at the structure—with only 9.8M shares outstanding and a float around 7.8M, this is a powder keg.
Yes, they filed a new
$2.8M ATM today to ensure they have the cash runway to keep building, but compared to an ~
$18M market cap, this is a lean setup. In a low-float biotech, that's exactly where the "massive potential" hides if volume surges. Science is the catalyst, supply/demand is the engine. Monitoring the ATM sell-through, but the bull case is clear. 🧪📈 #Biotech #ASCO2026 #SmallCap #LowFloat #Trading
